Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30072905 | 1.00 | TXNRD1 (0.37) | TXNRD1TXNRD3TXNRD2EPHB4ABCG2 | |
| Hydrochloric Acid SCHEMBL5090020 | 0.98 | TXNRD1 (0.36) | TXNRD1TXNRD3TXNRD2EPHB4ABCG2 | |
| SCHEMBL16703954 | 0.83 | MAPT (0.37) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL11547575 | 0.78 | TXNRD1 (0.39) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 | |
| Hydrochloric Acid SCHEMBL30749426 | 0.77 | TXNRD1 (0.38) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 | |
| Hydrochloric Acid SCHEMBL31668880 | 0.77 | TXNRD1 (0.38) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 | |
| SCHEMBL14070149 | 0.76 | TDP1 (0.44) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 | |
| SCHEMBL25166001 | 0.75 | AOC3 (0.42) | TXNRD1TXNRD3TXNRD2EPHB4ABCG2 | |
| SCHEMBL4031896 | 0.75 | AOC3 (0.50) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 | |
| SCHEMBL14012978 | 0.75 | NQO2 (0.44) | TXNRD1TXNRD3TXNRD2ABCG2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | claimed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | claimed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | claimed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | claimed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | claimed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| CN-101115744-A | Process for preparing 4- (6-chloro-2, 3-methylenedioxyanilino) -7- [ 2- (4-methylpiperazin-1-yl) ethoxy ] -5-tetrahydropyran-4-yloxyquinazoline, intermediates and crystalline salts thereof | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | claimed |
| EP-1871769-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE,THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | claimed |
| WO-2006064217-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3778589-B1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | TXNRD1 4069/4885TXNRD3 3674/4885TXNRD2 4618/4885 |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | TXNRD1 4014/4885TXNRD3 4666/4885TXNRD2 3727/4885 |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | TXNRD1 2023/4885TXNRD3 2990/4885TXNRD2 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.